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Cannabinoid CB2 receptors are expressed by immune cells and almost absent in healthy brain but under pathological conditions,
their expression in the brain increases. This specific increase in CB2 expression makes this protein an ideal target for drugs aimed
at regulating neuropathologies, including chronic brain inflammations and tumors. Here, Sexton et al. developed a novel molecular
imaging agent, NIR-mbc94, which selectively binds to CB2 receptors. Upon interaction with CB2 receptors, it emits a signal that is
easily detected and thus allows for unbiased high-throughput screening of compounds interacting with this therapeutic target.Attacking Airway Inflammation with Bisdionin F
PAGE 569
Acidic mammalian chitinase (AMCase) has been identified as a mediator of allergic inflamma-
tion and asthma. In this study, a rational approach was used by Sutherland et al. to design
a selective AMCase inhibitor, bisdionin F, which was effective in vivo and attenuated several
aspects of allergic inflammation. Unexpectedly, bisdionin F treatment led to a striking
enhancement of inflammatory neutrophils in allergic animals, revealing new functions for
AMCase and also raising questions about the therapeutic potential of chitinase inhibition.
However, this inhibitor class could potentially be developed to be active against chitinase-
like proteins, which have also been implicated in asthma.Vaccine Candidate for Clostridium difficile
PAGE 580
Nosocomial infections with the Gram-positive pathogen Clostridium difficile pose a major risk for hospitalized patients and result in
significant costs to health care systems. In this study, a hexasaccharide-hapten of theClostridium difficile PS-II cell surface polysac-
charide was synthesized and microarrays were manufactured, which were used by Oberli et al. to identify antibodies recognizing the
synthetic structure in patient stool samples. Mice immunized with the corresponding neoglycoconjugate produced antibodies, thus
indicating that the PS-II glycopolymer is recognized by the immune system upon infection and constitutes a viable vaccine candidate
against C. difficile.
Deciphering Antibiotic Inhibition
PAGE 589
The ribosome is a major target in the bacterial cell for antibiotics. Therefore, insight into how antibiotics inhibit ribosome function can
provide not only information regarding the fundamental process of translation but is also important for the development of new anti-
microbial agents to overcome the rise in multidrug-resistant bacteria. Among the current clinically used antibiotics, the thiopeptide
and orthosomycin antibiotics have unique binding sites on the large ribosomal subunit. Here, Mikolajka et al. show that these thio-
peptide and orthosomycin antibiotics exhibit differential effects on translational GTPases, thereby providingmechanistic insights into
the antibiotic inhibition of distinct steps during protein synthesis.Diversifying the Antibiotic Biosynthesis Repertoire
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In this study, Evans et al. reengineer an antibiotic assembly line toproduce newderivatives of
the antibacterial agent andrimid. Previous antibiotic synthetase reengineering studies have
primarily relied on domain swapping strategies, in which nearly intact enzymes are swapped
betweenpathways to yield a change in the final product. This study usesdirectedevolution in
order to effect a change in the final product, with the advantage that multiple ‘‘unnatural’’
natural products can be generated at once. This advance in diversifying antibiotic biosyn-
thetic pathwayswas accomplished by Evans et al. with the development of high-throughput
LC-MS/MS for screening mutant libraries.New Tools to Target the Proteasome
PAGE 608
Proteasome inhibitors have proven to be valuable tools to study proteasome biology and one particular compound, bortezomib, is
used for the treatment of multiple myeloma. The majority of proteasome inhibitors primarily target chymotrypsin-like sites of these
proteolytic complexes. Although highly specific cell-permeable inhibitors of caspase-like sites became available recently, the
synthesis of cell-permeable inhibitors of trypsin-like sites has proven technically challenging. Here, the Kisselev and Overkleeft labo-
ratories describe the development and characterization of such compounds as well as the development of a full palette of tools
needed to manipulate individual proteasome active sites in living cells.Chemistry & Biology 18, May 27, 2011 ª2011 Elsevier Ltd All rights reserved v
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Small molecule-dependent inteins enable protein structure and function to be controlled posttranslationally in living cells. Starting
with two previously evolved ligand-dependent inteins that splice in a manner that is dependent on 4-hydroxytamoxifen (4-HT),
Peck et al. evolved second-generation inteins with substantially improved splicing efficiency in both yeast and mammalian cells.
These newly evolved inteins typically resulted in 50%–90% of spliced protein in the presence of 4-HT and less than 5% splicing
in the absence of 4-HT. These second-generation evolved inteins augment the promise of ligand-dependent protein splicing as
an effective and general approach to probing protein function in mammalian cells.vi Chemistry & Biology 18, May 27, 2011 ªUA62784: Arresting Cancer in Mitosis
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A recent screen for compounds that selectively targeted pancreatic cancer cells isolated
UA62784. Here, Tcherniuk et al. found that UA62784 inhibits microtubule polymerization
in vitro and interacts with tubulin dimers at or near the colchicine-binding site ten times
more potently than colchicine, vinblastine, or nocodazole. Nanomolar doses of UA62784
promote the accumulation of mammalian cells in mitosis owing to aberrant mitotic spin-
dles. They authors also show that effects of UA62784 and of some known microtubule-
depolymerizing drugs are additive and that low doses of UA62784 and vinblastine
potentiate each other to inhibit proliferation.
New Screen for Probing Oxygenases
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2-Oxoglutarate (2-OG) dependent oxygenases catalyze hydroxylation and N-methyl de-methylation reactions that are important in oxygen sensing and the control of gene expression. They constitute therapeutic targets
for the treatment of anemia, ischemic diseases, and cancer. Here, Rotili et al. demonstrate the usefulness of a probe-based approach
that employs photo cross-linking and affinity purification for the identification of 2-OG oxygenases and their interaction with inhibitors
in cell extracts. The approach was validated using the therapeutically relevant oxygenases HIF-a hydroxylase and a histone deme-
thylase. The authors also demonstrate that this probe approach has the potential to capture substrates.Lysobactin Synthesis: Termination in Tandem
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Lysobactin is a macrocyclic depsipeptide that displays a very strong activity against path-
ogenic Gram-positive bacteria and is considered a potent agent for treatment of bacterial
infections caused by resistant pathogens. In this work, Hou et al. have identified and char-
acterized the entire lysobactin biosynthetic gene cluster, which reveals an NRPS-based
assembly. The association between the synthetases and lysobactin was confirmed by
investigating the adenylation domain specificities in vitro. Analysis of the unusual tandem
thioesterase domain architecture revealed that the penultimate TE domain mediates the
cyclization of lysobactin, whereas the final TE is suggested to govern regeneration of the
assembly line.
Burkholderia’s Antibiotic Treasure Trove Revealed
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To combat the emergence of multidrug-resistant bacteria, new antibiotics are urgently needed. Here, Mahenthiralingam et al. iden-
tified that the bacterium Burkholderia ambifaria produces a potent antibiotic called enacyloxin that kills a range of drug-resistant
bacteria. They mapped the enacyloxin production genes and found that they encoded an unusual mixture of antibiotic-producing
enzymes (polyketide synthases) that are normally associated with the Streptomyces group of bacteria, which produce most of
our useful antibiotics. These findings suggest thatBurkholderia bacteria are a promising resource for the discovery of new antibiotics,
with unique production pathways and potent activity against drug-resistant bacteria.2011 Elsevier Ltd All rights reserved
